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The aim of the study was to establish relationships between the 
parameters of lipid metabolism, the severity of liver steatosis and the 
concentration of endothelial lipase (EL) serum levels depending on the 
state of carbohydrate metabolism and the presence of type 2 diabetes . 
60 patients with non-alcoholic fatty liver disease (NAFLD) on the 
background of hypertension and overweight have been examined. The 
distribution of the examined patients was carried out in the following groups: 
group 1 - patients with hypertension without an increase in NAFLD liver fat 
score normal weight  (n = 8); Group 2 - with hypertension without increse in 
NAFLD liver fat score with overweight (n = 8); group 3 - with liver steatosis 
without type 2 diabetes (n = 10); group 4 - with liver steatosis and type 2 
diabetes (n = 10); group 5 - with laboratory signs of steatohepatitis without 
type 2 diabetes (n = 16); group 6 - with laboratory signs of steatohepatitis 
and type 2 diabetes (n = 8). All patients were divided with accordance of 
age and sex. The control group consisted of 20 healthy individuals. 
All patients with NAFLD on the background of hypertension and the 
presence of type 2 diabetes had significantly (p <0.001) higher 
hyperinsulinism (32.27 + 4.71 vs. 20.75 + 9.5 mkU/ml) and significantly (p 
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<0.001) increased values of insulin resistance index HOMA-IR (9.52 + 4.21 
against 4.76 + 2.23 U), which testifies in favour of type 2 diabetes. 
In all patients with NAFLD on the background of hypertension, there 
are proatherogenic changes in lipid status, the presence of which is 
exacerbated with obesity and the severity of steatosis. It is most evident in 
patients with steatohepatitis in combination with type 2 diabetes. 
The level of EL is significantly higher in patients with steatosis, 
regardless of the presence of diabetes and with steatohepatitis without 
diabetes compared with controls and patients with hypertension and normal 
weight. Significantly high levels of endothelial lipase were found in patients 
with steatohepatitis and diabetes. Correlation analysis between the HbA1c 
and EL levels showed a reliable direct relationship between the parameters. 
So the level of EL in patients with hypertension in combination with the 
severity of liver steatosis is significant relative to atherosclerotic vascular 
lesions and prognostic as the occurrence of cardiovascular complications. 
Keywords: NAFLD, hypertension, type 2 diabetes, endothelial lipase, 
insulin resistance 
 
Introduction. Non-alcoholic fatty liver disease (NAFLD) is one of the 
most actual problems of modern medicine. Every year its prevalence 
increases, requiring even more attention to this problem [1, p. 261-271]. 
NAFLD is found in 20-30% of the population of Western European countries 
and the United States and 15% of the population of Asia [2, p. 33-38]. 
According to G. Marchesini et al. (2001), 67% of patients with NAFLD suffer 
from overweight; 57% have disorders of glucose tolerance, 47% have 
hypertriglyceridemia, 27% have low alpha cholesterol, 17% have 
hypertension [3, p. 873-880]. 
A generalized model of the pathogenesis of NAFLD was previously 
recognized as the "theory of two strikes," according to which the "first strike" 
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is the increase in the intake of free fatty acids (FFA) in the liver. 
Accumulation of fat in hepatocytes is a consequence of increased intake of 
FFA from adipose tissue, reducing the rate of their oxidation in 
mitochondria, and excess synthesis of FFAs from acetylcoenzyme A. 
Increasing the flow of FFA and reducing the rate of their oxidation leads to 
esterification of FFA with excessive formation of triglycerides in hepatocytes 
and secretion of increased amounts of cholesterol of very low density 
lipoprotein (VLDL), which contribute to the enhancement of free radical lipid 
oxidation and the accumulation of products of their peroxidation ("second 
strike") [4]. 
NAFLD in the background of overweight or obesity suggests disorders 
of adipose tissue secretion of hormones adipokines, which reduces tissue 
sensitivity to insulin by reducing adiponectin levels and increasing levels of 
visfatin and resistin, as well as increasing the level of chemokines that 
activate macrophages and promote their accumulation in fatty tissue. 
Activated macrophages produce cytokines that negatively affect sensitivity 
to insulin [5]. 
According to most researchers, the clinical significance of NAFLD is 
associated with the genesis of atherosclerosis [6], which allows NAFLD to 
be considered as an independent risk factor for the development of 
cardiovascular disease (CVD) [16]. As triggers, associated with the 
development of NAFLD and metabolic disorders, oxidative stress, 
inflammation, dyslipidemia, IR, abdominal obesity, low adiponectin levels, 
endothelial dysfunction and postprandial dyslipidemia are reported [7, p. 
8407-8415]. The relationship between NAFLD and CVD was first 
established in relation to patients with type 2 diabetes [8, p. 479-482]. 
Insulin resistance (IP) is a disturbed biological response of the 
peripheral tissues of an organism to the effect of endogenous or exogenous 
insulin, manifested in the regulation of the metabolism of carbohydrates, 
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proteins, fats, growth processes, tissue differentiation, DNA synthesis, gene 
transcription. Therefore, the modern concept of IP is not limited to 
parameters that characterize exclusively the exchange of glucose. The 
greatest clinical significance is the loss of sensitivity to insulin of fatty, liver 
and muscle tissue [9, p. 2701-2704]. IR of liver tissue is accompanied by a 
decrease in the synthesis of glycogen, the activation of its processes of 
dissociation to glucose, the synthesis of glucose from amino acids, lactate, 
pyruvate, glycerol. Changes in the metabolism of glucose and lipids in the 
adipose tissue are an important pathogenetic link that leads to increased 
lipolysis, increased release of free fatty acids (FFA), triglycerides (TG) 
entering the liver, which become the main source of formation of very low 
density atherogenic lipoprotein (VLDL) and increased sedimentation of 
adipose tissue in the liver itself [10]. It enhances hepatic insulin resistance. 
In the liver there is an increase in the utilization of FFA, which leads to 
compensatory hyperinsulinaemia and the beginning of a cascade of 
reactions for the transformation of lipids in the blood. So the development of 
fatty liver dystrophy is a result of increased intake, excess synthesis and a 
decrease in the rate of β-oxidation of FFA in mitochondria, increased 
formotion and secretion of VLDL [11]. 
Cardiovascular mortality in patients with diabetes is in 3-4 times higher 
than in people without diabetes [12]. There is clinical evidence that 
hyperinsulinemia is an independent risk factor for developing CVD in people 
without diabetes. Insulin is able to exert a direct atherogenic effect on the 
walls of the vessels, causing proliferation and migration of smooth muscle 
cells, lipid synthesis in them, proliferation of fibroblasts, activation of the 
blood coagulation system, and decreased activity of fibrinolysis. So 
hyperinsulinemia makes a significant contribution to the development and 
progression of cardiovascular risk [13]. 
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It has now been proven that IR and endothelial dysfunction are the 
links of the same process and play an important role in the formation of 
metabolic disorders and, as a consequence, CVD. It is endothelial 
dysfunction that leads to the formation of atherosclerosis and 
predetermines the development of atherothrombosis [14]. 
Endothelial cells liner vessels from the inside and serve as a border 
between blood and tissues, which makes the endothelium vulnerable to 
various factors such as hypercholesterolemia, hyperglycemia, free radicals, 
high hydrostatic pressure, smoking, etc. Endothelial damage leads to a 
decrease in the release of endothelium-relaxing factors, which increases 
the formation of vasoconstrictive factors that forms endothelial dysfunction 
[15, p. 494–511]. 
Endothelial lipase (EL) is identified as a new member of the family of 
triglycerides and is very similar to lipoprotein lipase and hepatic lipase, but 
is a more sensitive marker of phospholipid hydrolysis. EL is the only lipase 
synthesized by endothelial cells. Data from laboratory studies have shown 
that EL can play a key role in modulating the metabolism of high density 
lipoproteins and contributes to the metabolism of atherogenic apoB-
containing lipoproteins. An increase in the plasma concentration of EL is 
associated with an increase in triglycerides and the concentration of 
apolipoprotein B in plasma. These facts suggest that EL is one of the key 
regulatory lipid metabolism enzymes [16]. Numerous studies also show that 
EL is a new marker of cardiovascular risk, which is closely related to 
dyslipidemia and insulin resistance [17]. 
Aims and methods. The aim of the study was to establish a 
relationship between the parameters of lipid metabolism, the severity of 
liver steatosis and the concentration of blood serum EL levels, depending 
on the state of carbohydrate metabolism and the presence of type 2 
diabetes. 
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The work has been performed on the basis of the National Institute of 
Therapy named by L.T. Malaya of National Academy of Medical Sciences 
of Ukraine within the department's research work of the department of 
internal medicine №1 of Kharkiv National Medical University "Clinical 
significance of markers of inflammation and metabolic disorders in patients 
with NAFLD taking into account comorbidity". 
The research was approved by the Ethics Commission of the Kharkiv 
National Medical University and conducted in accordance with the 
principles of the Helsinki Declaration. All patients signed an informed 
consent to participate in the study.  
60 patients with NAFLD on the backdrop of hypertension and 
overweight have been examined.  The NAFLD diagnosis was established in 
accordance with the Protocol of the Ministry of Health of Ukraine dated 
November 6, 2014, based on the criteria of the American Association for 
the Study of Liver Diseases [18, p. 2005-2023] and European 
Recommendations for the Diagnosis and Treatment of NAFLD [19, p. 65-
90]. The diagnosis of hypertension is in accordance with the Protocol No. 
384 of the Ministry of Health of Ukraine dated May 24, 2012, determining 
the stage and degree of hypertension is according to the clinical guidelines 
for arterial hypertension (2013) of the European Society for Hypertension 
(ESH) and the European Society of Cardiology (ESC) [20, p. 193-278]. The 
diagnosis of steatohepatitis was established in the presence of ultrasound 
data, elevated liver transaminases and the NAFLD liver fat score. 
The analysis of carbohydrate metabolism parameters in patients with 
NAFLD on the backdrop of hypertension and overweight found 18 patients 
with signs of type 2 diabetes with glycated haemoglobin level higher than 
6.5 mmol/l and / or hyperglycemia higher than 6.1 mmol/l. Given the fact 
that the presence of diabetes mellitus plays a pathogenic role in the 
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formation of liver steatosis [21, p. 479-482.], we conducted the distribution 
of the examined patients into the following groups: 
Group 1 - with hypertension without increasing NAFLD liver fat 
score with normal weight (n = 8)  
Group 2 - with hypertension without increased NAFLD liver fat 
score with overweight (n = 8) 
Group 3 - with liver steatosis without type 2 diabetes (n = 10) 
Group 4 - with liver steatosis and type 2 diabetes (n = 10) 
Group 5 - with laboratory signs of steatohepatitis without type 2 
diabetes (n = 16) 
Group 6 - with laboratory signs of steatohepatitis and type 2 
diabetes (n = 8) 
The control group consisted of 20 practically healthy individuals. All 
patients were divided with accordance of age and sex. 
The exclusion criteria were: acute and chronic inflammatory processes 
in the period of exacerbation of any localization; age over 60 and under 45 
(excluding the non-informative age for comorbidity of these pathologies 
[14]); obesity of the third degree and above; diffuse connective tissue 
diseases; oncological diseases; symptomatic hypertension; viral (HBV-, 
HCV-, HDV), toxic and medicated hepatitis; alcohol abuse (more than 30g 
of ethanol or 3.75 alcohol units per day for men and 20g or 2.5 alcoholic 
units for women); diabetes mellitus type I; hypertension of III stage and 
above; anamnesis data for Wilson-Konovalov's disease, idiopathic 
hemochromatosis and congenital failure of α1-antitrypsin; coronary heart 
disease  with postinfarction cardiosclerosis; heart failure of stage III; 
hypothyroidism and hyperthyroidism; refusal of the patient at any stage of 
the study. 
The body mass index (BMI) and measured the waist circumference 
(WC) have been accessed for all patients. Measurement of blood pressure 
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(BP) was performed according to the standard auscultatory method by N.S. 
Korotkov (office measurement) using a sphygmomanometer No. 31304500 
(Erka, Chemnitz, Germany). 
In order to monitor the implementation of dietary recommendations, a 
questionnaire was used in which patients, in which patients were 
questioned about the use of 15 main "forbidden" foods. The suggested 
answers included options of frequency of intake of products - every day; 
several times a week; several times a month; several times a year; never - 
that had a gradation of points from 4 to 0, respectively. The sum of points 
was evaluated as: 0-15 - coefficient 0: dietary recommendations were 
observed almost without breaks; 15-30 - coefficient 1: dietary 
recommendations were followed by rare breaks; 30-45 - coefficient 2: 
dietary recommendations were followed by frequent breaks; 45-60 - 
coefficient 3: dietary recommendations were practically not respected. 
The ultrasound of the abdominal cavity was performed by using 
ultrasound diagnostic systems with Doppler LOGIQ 5 (No. 1822SU6, 2003) 
and Vivid 3 (metrology No. 6009, 2004). 
With the purpose of excluding of an alcoholic genesis of NAFLD all 
patients underwent questioning for definition of alcohol units by the formula: 
Alcohol units = amount (liters) × alcoholic strength (%) × 0.789   
Alcohol abuse was excluded in cases if use of alcohol was less than 
30g of ethanol or 3.75 alcohol units per day for men (or 14 units per week) 
and 20g or 2.5 alcohol units for women (or 8 units per week). 
Glucose concentration in venous blood was determined by photometric 
method using an automatic biochemical analyzer - general purpose 
photometer "Humalyzer 2000", (metrology No. 18300 - 5397, Germany). To 
assess long-term carbohydrate metabolism compensation, the 
concentration of glycated haemoglobin (HbA1c) was determined using the 
kit "Reagent" (Ukraine) by reaction with thiobarbituric acid. The 
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concentration of insulin was determined by ELISA using the DRG reagent 
kit (USA). 
For the quantitative assessment of the severity of insulin resistance, 
the mathematical model HOMA-IR was used: 
HOMA-IR = (fasting insulin (U / mL) x fasting glucose (mmol / L))/22.5.  
If HOMA-IR was ≥ 2.77 it was considered as the presence of insulin 
resistance. 
For the liver steatosis identification, the NAFLD liver fat score was used 
according to the formula: 
NAFLD liver fat score= - 2.89+1.18×metabolic syndrome 
(yes=1/no=0)+ 0.45×type 2 diabetes (yes=2/no=0)+0.15× fasting serum 
Insulin (mU/L)+ 0.04 × fasting serum АSТ(U/L) – 0.94 × АSТ/АLТ. 
The concentration of EL serum was determined by ELISA using kits of 
reagents "Aviscera Bioscience INC" (USA). 
Statistical processing of the results of the study was conducted using 
Microsoft Exel and Statistica 7.0 programs using standard methods of 
virological statistics. 
Results of study. In all patients with NAFLD on the background of 
hypertension and type 2 diabetes, significantly (p <0.001) higher 
hyperinsulinism (32.27 + 4,71 versus 20.75 + 9.5 mkU/ml) and significantly 
(p <0.001) increased index of insulin resistance of HOMA-IR (9.52 + 4.21 
versus 4.76 + 2.23 USD) was detected. This fact proves the presence of the 
type 2 of diabetes. It should be noted that patients with type 2 diabetes in 
the hypertension group without increasing NAFLD liver fat score were not 
observed at all, 10 people with type 2 diabetes have liver steatosis and 8 
ones have laboratory signs of steatohepatitis. 
The level of systolic and diastolic blood pressure in all study groups 
was higher than one in the control group. It confirms the presence of 
hypertension in all patients in the main groups (tab. 1). 
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Table 1 
Anthropometric parameters of patients with hypertension 
according to the severity of liver steatosis and the presence of type 2 
diabetes 
Parameter 
Cont
rol 
grou
p 
(n=20
) 
  
 group 
1 
(n=8) 
group 2 
(n=8) 
group 3 
(n=10) 
group 
4 
(n=10) 
group 5 
(n=16) 
group 6 
(n=8) 
SBP, 
mmHg 
Mean 116 156,43* 165,56* 166,67* 
161,11
* 165,94* 175,63* 
SD 4,16 12,86 12,61 18,02 17,63 17,05 15,41 
SE 0,93 4,64 4,21 6,01 5,87 4,26 5,75 
DBP, 
mmHg 
Mean 73,5 98,57* 103,88* 101,11* 104,44* 101,56* 101,25* 
SD 5,15 6,26 7,81 3,33 11,3 10,28 9,91 
SE 1,15 2,36 2,61 1,11 3,76 2,57 3,51 
BMI, 
kg/m2 
Mean 21,43 23,12 28,07* 30,43* 29,57* 28,1* 30,91* 
SD 1,56 2,85 1,91 2,81 2,85 4,24 7,25 
SE 0,35 1,08 0,63 0,88 0,9 1,06 2,56 
WC, cm 
Mean 75,5 74,57 83* 95,2* 100,95* 103,53* 105,25* 
SD 6,83 6,92 8,18 9,51 11,19 8,41 9,66 
SE 1,52 2,61 2,72 3 3,54 2,1 3,41 
WC/ 
height, 
units. 
Mean 0,44 0,44 0,5* 0,55* 0,57* 0,59* 0,61* 
SD 0,033 0,042 0,026 0,045 0,042 0,035 0,031 
SE 0,007 0,016 0,009 0,014 0,011 0,008 0,006 
Note * The difference in parameters is statistically significant (р < 0,05) 
However, there is no significant difference between the study groups, 
which reduces the difference between the groups in parameters of 
hypertension. The only investigated subgroup, which differs from other by 
significantly higher values of SBP is a group of patients with laboratory 
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signs of steatohepatitis and diabetes mellitus. At the same time, DBP in this 
group is not significantly different from other groups. 
The analysis of anthropometric parameters showed that the overweight 
is significantly more evident in all patients from the studied groups 
compared to the control. BMI is also significantly lower in group of patients 
with hypertension without overweight. BMI of patients of other groups was 
not significantly different. Therefore, the subgroup of patients with 
hypertension and overweight has the right to exist as a separate subgroup 
There is a significant fact that patients from 2-6 subgroups have an 
equivalent degree of overweight, which in average values corresponds to 
1st degree of obesity. 
The waist circumference and waist circumference ratio to height did not 
differ between controls and group of hypertension without overweight. 
However, patients with steatosis and steatohepatitis on the background of 
hypertension had an abdominal type of fat distribution, the degree of which 
was higher than that of patients who had overweight and hypertension. The 
expressiveness of abdominal fat distribution (by the ratio of the waist 
circumference to height that had no gender difference) was most evident in 
patients of group 6 (with NAFLD, diabetes, overweight and hypertension). 
Levels of liver transaminases and alkaline phosphatase (AP) were not 
significantly different in patients with steatosis on the background of 
hypertension and in patients with hypertension without increased NAFLD 
liver fat score, but in patients with laboratory evidence of steatohepatitis 
there is a significant increase in these parameters. Moreover, attention is 
paid to the significant increase in the ALT/AST ratio in patients with 
steatohepatitis with type 2 diabetes (Tab. 2). 
The nutrition style in the groups is approximately the same and does 
not differ significantly from the control group. It shoul be noted that the 
consumption of alcohol in patients in the control group and in the 
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hypertension group without increasing NAFLD liver fat score is not 
significantly different from each other. In patients with steatosis of the liver 
and steatohepatitis alcohol use was significantly more in amount regardless 
of the presence of type 2 diabetes. 
A detailed analysis of the parameters of carbohydrate metabolism of 
patients with hypertension in relation to the severity of liver steatosis and 
the presence of type 2 diabetes is presented in Table. 3. It is evident that 
fasting glucose levels have normal values in patients with normal weight 
and hypertension, but they are significantly higher in patients with 
overweight and hypertension (but does not differ from the reference 
values). 
Table 2 
Transaminases, alkaline phosphatase, dietary and alcohol 
regimens, depending on the severity of liver steatosis and the 
presence of diabetes mellitus 
Parameter 
Control 
group 
(n=20) 
  
 group 
1 
(n=8) 
group 
2 
(n=8) 
group 3 
(n=10) 
group 4 
(n=10) 
group 5 
(n=16) 
AP, 
mmol/l 
Mean 1637,5 1279,17* 
1338,3
3 
1536,33
* 2083,54* 2376,66* 
SD 252,37 254,58 328,67 416,27 279,38 324,55 
SE 126,18 103,93 134,18 138,75 126,95 132,49 
ALT, U/l 
Mean 21* 23,55* 25,91* 23,4* 64,06* 59,51* 
SD 6,35 6,38 8,97 5,01 19,24 15,9 
SE 2,4 2,12 2,83 1,58 12,31 5,62 
AST, 
U/l 
Mean 23,28* 25,55* 23,1* 22,7* 44,06* 28,11 
SD 4,23 9,96 6,08 13,48 13,14 7,94 
SE 1,59 3,32 1,92 4,26 4,78 2,81 
ALT/ 
AST, 
units. 
Mean 0,897* 0,999* 1,151* 1,237* 1,469* 2,301* 
SD 0,176 0,307 0,311 0,541 0,454 1 
SE 0,066 0,102 0,098 0,171 0,113 0,354 
Diet 
Mean 2,666 2,5* 2,857* 2,428 2,125* 2, 41 
SD 0,577 0,577 1,463 0,786 0,834 0,94 
SE 0,333 0,288 0,553 0,297 0,295 0,447 
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Alcohol 
units 
Mean 3,628* 4,8* 6,39* 6,39* 7,281* 6,87* 
SD 1,127 2,135 3,725 2,22 2,738 2,565 
SE 0,426 0,711 1,178 0,702 0,684 0,89 
Note * The difference in parameters between groups is statistically significant (р < 
0,05) 
In patients with steatosis and with laboratory evidence of 
steatohepatitis without diabetes fasting glucose is significantly lower than in 
diabetics. The levels of glucose in patients with steatosis and 
steatohepatitis are not higher than average values, but have a significant 
tendency to increase in steatohepatitis (p <0.01). At the same time, 
glycemia does not differ significantly in patients with steatosis and 
steatohepatitis with diabetes mellitus (p = 0.47). 
Table 3 
Carbohydrate parameters of patients with hypertension in 
accordance to the severity of liver steatosis and the presence of 
diabetes 
Parameter 
 group 
1 
(n=8) 
group 2 
(n=8) 
group 
3 
(n=10) 
group 
4 
(n=10) 
group 
5 
(n=16) 
group 
6 
(n=8) 
Fasting 
glucose
,  
mmol/l 
Mean 4,82* 5,17* 5,27* 7,35* 5,38* 6,39* 
SD 0,33 0,74 0,33 1,97 0,58 1,07 
SE 0,12 0,26 0,11 0,62 0,15 0,38 
Fasting 
Insulin, Mean 13,27* 20,97* 18,64* 30,37* 32,82* 34,18* 
mkU/l SD 3,21 6,7 9,75 11,58 20,51 19,68 
  SE 1,66 2,53 3,08 3,61 5,12 6,96 
HOMA-
IR, 
units 
Mean 2,336* 4,484* 4,338* 9,691* 7,918* 9,211* 
SD 1,604 1,477 2,337 5,143 5,652 4,577 
SE 0,301 0,558 0,739 1,626 1,413 1,618 
HbA1C, 
% 
Mean 5,211* 5,54* 5,336* 7,947* 5,235* 7,893* 
SD 0,591 0,661 0,581 1,555 0,438 0,41 
SE 0,223 0,22 0,183 0,492 0,109 0,144 
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Note * The difference between the groups is statistically significant (р < 0,05) 
The concentration of insulin in patients with liver steatosis is higher in 
the presence of diabetes (p = 0.024). However, in patients with 
steatohepatitis, the level of insulin is high, but does not differ significantly in 
groups regarding the presence of diabetes. An analysis of the concentration 
of insulin in hypertensive patients without overweight is significant (p <0.01) 
lower than in patients with overweight. 
Accordingly, the HOMA-IR index does not significantly differ in patients 
with hypertension and overweight and in patients with liver steatosis without 
diabetes (p = 0.87). However, values in patients with steatosis without 
diabetes are significantly lower than ones in patients with steatosis and 
diabetes and lower than ones of both subgroups with steatohepatitis (p 
<0.01). Also, the HOMA-IR index is in the range of normal values in 
hypertensive patients without overweight and is significantly higher in 
hypertensive patients with overweight (p <0.01). 
In patients with hypertension and with and without overweight, as well 
as in patients with steatosis or steatohepatitis without diabetes is not 
significantly different and is within the range of normal values. In patients 
with diabetes mellitus, HbA1c is higher than in ones without diabetes, 
regardless of whether there is steatosis or steatohepatitis, since no 
significant difference is found among these subgroups (p = 0.97). 
The level of total cholesterol is elevated relative to normal values in 
patients with hypertension, regardless of the degree of overweight. It also 
grows due to the severity of steatosis. The most notable difference is the 
difference between groups with and without type 2 diabetes. There are 
higher levels of total cholesterol in groups with steatosis and steatohepatitis 
in patients with type 2 diabetes (tab.4). 
The concentration of triglycerides increases from group to group. It also 
should be noted that there is difference between the groups with steatosis 
and steatohepatitis, and between groups with and without diabetes. 
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LDL concentrations are too high in patients with hypertension, 
regardless of the degree of overweight, but are also greater in the 
respective groups depending on presence of type 2 diabetes. There is a 
tendency to decrease in parameter HDL from group to group, but the 
smallest values are present in patients with steatohepatitis suffering from 
type 2 diabetes. And the level of HDL no longer reaches the protective 
values in patients with hypertension without increasing the NAFLD liver fat 
score, regardless of overweight. 
Table. 4. 
Parameters of lipid metabolism depending on the severity of liver 
steatosis and the presence of type 2 diabetes 
Parameter 
Contr
ol 
group 
(n=20) 
  
 group 
1 
(n=8) 
group 2 
(n=8) 
group 
3 
(n=10) 
group 
4 
(n=10) 
group 
5 
(n=16) 
Parameter 
Total 
cholest
erol, 
mmol/l 
Mean  3,85 5,541 5,02* 5,23* 6,07* 5,581* 6,242* 
SD  0,77 0,81 1,845 0,909 0,677 1,265 1,692 
SE  0,291 0,306 0,615 0,303 0,225 0,316 0,598 
Triglyc
erides, 
mmol/l 
Mean  0,92 1,251* 1,04* 1,575* 1,824* 1,785* 2,297* 
SD  0,16 0,462 0,308 0,632 1,007 1,217 1,051 
SE  0,06 0,174 0,163 0,21 0,335 0,304 0,371 
HDL, 
mmol/l 
Mean  1,77 1,44 1,49* 1,47 1,33 1,22 1,15* 
SD  0,28 0,31 0,22 0,33 0,24 0,28 0,24 
SE  0,11 0,13 0,17 0,11 0,11 0,07 0,11 
LDL, 
mmol/l 
Mean  2,36 3,698* 3,298 3,216* 3,753* 3,558* 4,253* 
SD  0,46 0,826 1,717 0,776 0,535 1,201 1,359 
SE  0,18 0,369 0,607 0,258 0,218 0,3 0,555 
Endoth
elial 
lipase, 
ng / ml 
Mean 8,231 9,56 11,299* 11,714* 
11,709
* 11,84* 15,51* 
SD 2,474 2,157 2,925 3,22 3,22 3,801 3,09 
SE 0,553 0,815 0,975 1,087 1,019 1,326 1,024 
Note * The difference in parameters compared to the control group is statistically 
significant (р < 0,05) 
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The concentration of endothelial lipase is not significantly different in 
the control group and in the group of patients with hypertension without 
increasing the NAFLD liver fat score. Its level is significantly higher in 
patients with steatosis, regardless of the presence of diabetes and 
steatohepatitis without diabetes compared with controls and patients with 
hypertension and normal weight. The highest level of endothelial lipase is in 
patients with steatohepatitis suffering from type 2 diabetes. Since the 
integral diagnostic criterion and compensation marker of diabetes is 
glycated hemoglobin, we have correlated between the level of HbA1C and 
endothelial lipase. This analysis showed a significant direct correlation 
between the parameters (Spearman R = 0.386, p <0.05). 
Conclusions. All NAFLD patients with hypertension have 
proatherogenic lipid status changes that increase with obesity and severity 
of steatosis and are most evident in steatohepatitis in combination with type 
2 diabetes. 
The level of hepatic transaminases and alkaline phosphatase in 
patients with laboratory evidence of steatohepatitis is significantly 
increased. Moreover, attention is paid to the significant increase in the 
ALT/AST ratio in patients with steatohepatitis and type 2 diabetes. 
Patients with liver steatosis and steatohepatitis drink alcohol 
significantly more than the control group and the group with hypertension 
without increasing the NAFLD liver fat score, regardless of the presence of 
type 2 diabetes. 
Correlation analysis between the level of HbA1C and endothelial lipase 
showed a significant direct correlation between the parameters. Therefore, 
the process of glycation of proteins at type 2 diabetes, which is associated 
with the formation of microangiopathy, is related to the activation of 
endothelial lipase, which can be considered as an additional factor of 
vascular damage. Taking into account the fact that in patients with 
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laboratory characteristics of steatohepatitis and type 2 diabetes that the 
highest levels of SBP are detected, the elevated levels of endothelial lipase 
should be considered as an additional risk factor. 
Therefore, the level of EL in patients with hypertension in combination 
with the severity of steatosis is significant for atherosclerotic vascular 
damage and prognostic as cardiovascular complications. At the same time, 
the prognosis is deteriorating with the presence of additional independent 
risk factors such as the presence of type 2 diabetes and increased alcohol 
use, which directly correlates with the severity of liver steatosis. 
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